DDInter1480 DDInter1376
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pit
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pitolisant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pitolisant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Pitolisant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Pitolisant {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Pitolisant {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Pitolisant may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Pitolisant may lead to a major life threatening interaction when taken with Pasireotide
Pitolisant may lead to a major life threatening interaction when taken with Ribociclib